EA005586B1 - Гибридный белок проинсулина и способ получения из него рекомбинантного инсулина - Google Patents

Гибридный белок проинсулина и способ получения из него рекомбинантного инсулина Download PDF

Info

Publication number: EA005586B1
Authority: EA; Eurasian Patent Office
Prior art keywords: chain; amino acid; dna; insulin; acid sequence
Prior art date: 1999-04-30

Application number

EA200101161A

Other languages

English (en)

Russian (ru)

Other versions

EA200101161A1 (ru

Inventor

Сусаку Ока

Сейдзи Сато

Наохико Хигасикуни

Масааки Кондо

Тосиюки Кудо

Сигеаки Ватанабе

Йосихиро Ваки

Хиротака Юки

Original Assignee

Итохам Фудс Инк.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-30

Filing date

2000-04-26

Publication date

2005-04-28

2000-04-26 Application filed by Итохам Фудс Инк. filed Critical Итохам Фудс Инк.

2002-06-27 Publication of EA200101161A1 publication Critical patent/EA200101161A1/ru

2005-04-28 Publication of EA005586B1 publication Critical patent/EA005586B1/ru

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 177
102000004877 Insulin Human genes 0.000 title claims abstract description 121
108090001061 Insulin Proteins 0.000 title claims abstract description 121
229940125396 insulin Drugs 0.000 title claims abstract description 86
238000000034 method Methods 0.000 title claims abstract description 46
108090000623 proteins and genes Proteins 0.000 title claims abstract description 43
102000004169 proteins and genes Human genes 0.000 title claims abstract description 40
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 49
102000037865 fusion proteins Human genes 0.000 claims abstract description 41
108020001507 fusion proteins Proteins 0.000 claims abstract description 41
108090000190 Thrombin Proteins 0.000 claims abstract description 29
229960004072 thrombin Drugs 0.000 claims abstract description 29
108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 23
125000000539 amino acid group Chemical group 0.000 claims abstract description 19
230000028327 secretion Effects 0.000 claims abstract description 11
210000004027 cell Anatomy 0.000 claims description 28
239000013598 vector Substances 0.000 claims description 25
241000894006 Bacteria Species 0.000 claims description 20
238000003776 cleavage reaction Methods 0.000 claims description 19
230000007017 scission Effects 0.000 claims description 19
239000001963 growth medium Substances 0.000 claims description 18
108010076181 Proinsulin Proteins 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 13
108090000087 Carboxypeptidase B Proteins 0.000 claims description 12
102000003670 Carboxypeptidase B Human genes 0.000 claims description 12
108700039691 Genetic Promoter Regions Proteins 0.000 claims description 8
230000002255 enzymatic effect Effects 0.000 claims description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 4
210000002421 cell wall Anatomy 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 3
238000012545 processing Methods 0.000 claims description 2
108020004414 DNA Proteins 0.000 description 145
239000000243 solution Substances 0.000 description 33
239000012634 fragment Substances 0.000 description 31
238000003752 polymerase chain reaction Methods 0.000 description 31
238000006243 chemical reaction Methods 0.000 description 29
235000018102 proteins Nutrition 0.000 description 28
150000001413 amino acids Chemical class 0.000 description 27
239000000047 product Substances 0.000 description 26
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 19
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
239000008280 blood Substances 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
230000002441 reversible effect Effects 0.000 description 12
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
239000008103 glucose Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 11
235000000346 sugar Nutrition 0.000 description 11
238000000137 annealing Methods 0.000 description 10
238000004925 denaturation Methods 0.000 description 10
230000036425 denaturation Effects 0.000 description 10
239000013604 expression vector Substances 0.000 description 10
229940103453 novolin Drugs 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 9
238000010828 elution Methods 0.000 description 9
239000002773 nucleotide Substances 0.000 description 9
125000003729 nucleotide group Chemical group 0.000 description 9
241000193830 Bacillus <bacterium> Species 0.000 description 8
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
238000001962 electrophoresis Methods 0.000 description 8
108091028043 Nucleic acid sequence Proteins 0.000 description 7
239000013612 plasmid Substances 0.000 description 7
108010066381 preproinsulin Proteins 0.000 description 7
108010075254 C-Peptide Proteins 0.000 description 6
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 6
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 6
239000011259 mixed solution Substances 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
210000000496 pancreas Anatomy 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
229920001817 Agar Polymers 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
101000976075 Homo sapiens Insulin Proteins 0.000 description 4
102000035195 Peptidases Human genes 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 4
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
239000008272 agar Substances 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
108010013359 miniproinsulin Proteins 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000012408 PCR amplification Methods 0.000 description 3
108010005991 Pork Regular Insulin Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
239000011543 agarose gel Substances 0.000 description 3
229940041514 candida albicans extract Drugs 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
239000012228 culture supernatant Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
229960003276 erythromycin Drugs 0.000 description 3
230000004927 fusion Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000013632 homeostatic process Effects 0.000 description 3
229940088597 hormone Drugs 0.000 description 3
239000005556 hormone Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 3
239000012138 yeast extract Substances 0.000 description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
101001011741 Bos taurus Insulin Proteins 0.000 description 2
101100192404 Caenorhabditis elegans ptr-9 gene Proteins 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
240000000731 Fagus sylvatica Species 0.000 description 2
235000010099 Fagus sylvatica Nutrition 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
101710085938 Matrix protein Proteins 0.000 description 2
101710127721 Membrane protein Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
102000019197 Superoxide Dismutase Human genes 0.000 description 2
108010012715 Superoxide dismutase Proteins 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
210000002472 endoplasmic reticulum Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
244000005700 microbiome Species 0.000 description 2
238000012510 peptide mapping method Methods 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
239000013600 plasmid vector Substances 0.000 description 2
238000004007 reversed phase HPLC Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 1
101150018711 AASS gene Proteins 0.000 description 1
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
241001135931 Anolis Species 0.000 description 1
241000448737 Bacillus luteus Species 0.000 description 1
101100324465 Caenorhabditis elegans arr-1 gene Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
108010013369 Enteropeptidase Proteins 0.000 description 1
102100029727 Enteropeptidase Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000581326 Homo sapiens Mediator of DNA damage checkpoint protein 1 Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
108010085169 Lysine carboxypeptidase Proteins 0.000 description 1
108010053229 Lysyl endopeptidase Proteins 0.000 description 1
102100027643 Mediator of DNA damage checkpoint protein 1 Human genes 0.000 description 1
241001460678 Napo <wasp> Species 0.000 description 1
IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 1
241000218998 Salicaceae Species 0.000 description 1
DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 description 1
241000078006 Shaka Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000007815 allergy Effects 0.000 description 1
235000012538 ammonium bicarbonate Nutrition 0.000 description 1
239000001099 ammonium carbonate Substances 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
150000003943 catecholamines Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
108090001092 clostripain Proteins 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000004026 insulin derivative Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
210000004457 myocytus nodalis Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Medicinal Chemistry (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)

EA200101161A 1999-04-30 2000-04-26 Гибридный белок проинсулина и способ получения из него рекомбинантного инсулина EA005586B1 (ru)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP12487799A JP3406244B2 (ja)	1999-04-30	1999-04-30	新規な融合蛋白質からの組み換えインスリンの製造方法
PCT/JP2000/002736 WO2000066738A1 (fr)	1999-04-30	2000-04-26	Procede de production d'insuline recombinee a partir d'une nouvelle proteine fusionnee

Publications (2)

Publication Number	Publication Date
EA200101161A1 EA200101161A1 (ru)	2002-06-27
EA005586B1 true EA005586B1 (ru)	2005-04-28

Family

ID=14896314

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EA200101161A EA005586B1 (ru)	1999-04-30	2000-04-26	Гибридный белок проинсулина и способ получения из него рекомбинантного инсулина

Country Status (14)

Country	Link
US (1)	US6841361B1 (fr)
EP (1)	EP1179593B1 (fr)
JP (1)	JP3406244B2 (fr)
KR (1)	KR100659671B1 (fr)
CN (1)	CN1213146C (fr)
AT (1)	ATE381619T1 (fr)
AU (1)	AU775471B2 (fr)
CA (1)	CA2372221A1 (fr)
DE (1)	DE60037508T2 (fr)
DK (1)	DK1179593T3 (fr)
EA (1)	EA005586B1 (fr)
HK (1)	HK1042113A1 (fr)
WO (1)	WO2000066738A1 (fr)
ZA (1)	ZA200108951B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2001241125A1 (en)	2000-03-14	2001-09-24	Itoham Foods Inc.	Process for producing polypeptide having disulfide bond
US7312192B2 (en) *	2001-09-07	2007-12-25	Biocon Limited	Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2003244053A1 (en) *	2003-06-03	2005-01-21	Shanghai Centre Of Research And Development Of New Drugs	A fusion protein suitable to be expressed high effectively and the production method thereof
BRPI0520622B8 (pt) *	2005-10-13	2021-05-25	Biocon Ltd	processo para o preparo de conjugados de insulina
US20100152419A1 (en) *	2008-02-12	2010-06-17	Itoham Foods Inc.	Fusion protein containing highly-expressed and secreted insulin precursor, dna encoding same, and method of producing insulin
JP6064912B2 (ja)	2011-10-25	2017-01-25	味の素株式会社	タンパク質の分泌生産法
KR102666154B1 (ko)	2018-08-08	2024-05-20	주식회사 대웅제약	지속형 인슐린 아날로그 및 그 복합체
KR102646845B1 (ko) *	2018-08-08	2024-03-14	주식회사 대웅제약	클로스트리파인을 이용한 지속형 인슐린 아날로그 복합체의 활성형 제조방법
US12435116B2 (en)	2019-10-16	2025-10-07	Clarence Hurt	Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
CN113773400B (zh) *	2020-06-09	2023-08-18	宁波鲲鹏生物科技有限公司	一种门冬胰岛素衍生物及其应用
CN113773392B (zh) *	2020-06-09	2023-04-07	宁波鲲鹏生物科技有限公司	一种甘精胰岛素的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4431740A (en)	1979-09-12	1984-02-14	The Regents Of The University Of California	DNA Transfer vector and transformed microorganism containing human proinsulin and pre-proinsulin genes
NZ196610A (en)	1980-03-27	1984-03-16	Lilly Co Eli	Preparation of insulin or insulin analog
NZ199391A (en) *	1981-01-02	1985-12-13	Genentech Inc	Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
JPH07108224B2 (ja) *	1985-11-07	1995-11-22	重三鵜高	バチルス・ブレビスを用いる遺伝子の発現方法
JPS6387980A (ja) *	1986-09-30	1988-04-19	Shikishima Boseki Kk	プラスミドベクタ−、菌株、及びそれを用いてペプシノ−ゲンを生産する方法
US5426036A (en) *	1987-05-05	1995-06-20	Hoechst Aktiengesellschaft	Processes for the preparation of foreign proteins in streptomycetes
DE3936876A1 (de)	1989-11-06	1991-05-23	Hoechst Ag	Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04126084A (ja)	1990-05-11	1992-04-27	Hoechst Japan Ltd	蛋白質の製造法
US5378613A (en) *	1991-09-24	1995-01-03	Eli Lilly And Company	Method for increased expression of low molecular weight recombinant polypeptides
DK0600372T3 (da) *	1992-12-02	1997-08-11	Hoechst Ag	Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
JP3164181B2 (ja) *	1993-03-01	2001-05-08	ヒゲタ醤油株式会社	新規発現ベクタ−、該発現ベクタ−を保有する微生物、該微生物を用いる有用物質の製造法
US6001604A (en) *	1993-12-29	1999-12-14	Bio-Technology General Corp.	Refolding of proinsulins without addition of reducing agents
DE4405179A1 (de)	1994-02-18	1995-08-24	Hoechst Ag	Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
HRP940432B1 (en) *	1994-08-05	2003-10-31	Pliva Pharm & Chem Works	Dna sequences encoding biosynthetic insulin precursors and process for preparation of insulin
EP0871474B2 (fr)	1994-12-29	2011-09-21	Ferring International Center S.A.	Production d'insuline humaine
KR0150565B1 (ko) *	1995-02-15	1998-08-17	김정재	유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
FR2732978B1 (fr) *	1995-04-14	1997-05-30	Inst Nat Sante Rech Med	Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
GB9513967D0 (en)	1995-07-08	1995-09-06	Univ Leicester	Insulin
JP3313083B2 (ja) *	1998-03-31	2002-08-12	伊藤ハム株式会社	新規な融合蛋白質をコ―ドするｄｎａおよびその発現を介する有用ポリペプチドの製造方法

1999
- 1999-04-30 JP JP12487799A patent/JP3406244B2/ja not_active Expired - Fee Related
2000
- 2000-04-26 US US09/959,548 patent/US6841361B1/en not_active Expired - Fee Related
- 2000-04-26 CN CNB008069344A patent/CN1213146C/zh not_active Expired - Fee Related
- 2000-04-26 DK DK00921035T patent/DK1179593T3/da active
- 2000-04-26 EA EA200101161A patent/EA005586B1/ru not_active IP Right Cessation
- 2000-04-26 WO PCT/JP2000/002736 patent/WO2000066738A1/fr active IP Right Grant
- 2000-04-26 KR KR1020017013921A patent/KR100659671B1/ko not_active Expired - Fee Related
- 2000-04-26 CA CA002372221A patent/CA2372221A1/fr not_active Abandoned
- 2000-04-26 AT AT00921035T patent/ATE381619T1/de not_active IP Right Cessation
- 2000-04-26 EP EP00921035A patent/EP1179593B1/fr not_active Expired - Lifetime
- 2000-04-26 AU AU41425/00A patent/AU775471B2/en not_active Ceased
- 2000-04-26 DE DE60037508T patent/DE60037508T2/de not_active Expired - Fee Related
- 2000-04-26 HK HK02103154.4A patent/HK1042113A1/en unknown
2001
- 2001-10-30 ZA ZA200108951A patent/ZA200108951B/en unknown

Also Published As

Publication number	Publication date
ATE381619T1 (de)	2008-01-15
EP1179593A1 (fr)	2002-02-13
EA200101161A1 (ru)	2002-06-27
WO2000066738A1 (fr)	2000-11-09
CN1350584A (zh)	2002-05-22
CN1213146C (zh)	2005-08-03
ZA200108951B (en)	2002-10-30
HK1042113A1 (en)	2002-08-02
EP1179593B1 (fr)	2007-12-19
DE60037508D1 (de)	2008-01-31
AU4142500A (en)	2000-11-17
US6841361B1 (en)	2005-01-11
KR100659671B1 (ko)	2006-12-21
AU775471B2 (en)	2004-08-05
KR20020018192A (ko)	2002-03-07
CA2372221A1 (fr)	2000-11-09
JP3406244B2 (ja)	2003-05-12
JP2000316579A (ja)	2000-11-21
DK1179593T3 (da)	2008-04-28
DE60037508T2 (de)	2008-12-11
EP1179593A4 (fr)	2003-04-16

Publication	Publication Date	Title
US20100210815A1 (en)	2010-08-19	Insulin production methods and pro-insulin constructs
EP0055945A2 (fr)	1982-07-14	Proinsuline humaine, ses analogues, méthode de préparation par expression polypeptidique microbienne et sa conversion en insuline humaine
JPH08333395A (ja)	1996-12-17	ヒトプロインスリン誘導体およびヒトインスリンの製造方法
IE914347A1 (en)	1992-06-17	Fusion polypeptides
WO1995017510A1 (fr)	1995-06-29	Procede de production d'un peptide i du type glucagon
EA005586B1 (ru)	2005-04-28	Гибридный белок проинсулина и способ получения из него рекомбинантного инсулина
JP7266325B2 (ja)	2023-04-28	蛍光タンパク質フラグメントを含む融合タンパク質およびその用途
JP2009542235A (ja)	2009-12-03	二塩基性ｂ鎖末端を有するインスリン類似体の生産方法
US5218093A (en)	1993-06-08	EGF variants and pharmaceutical use thereof
CN114292338B (zh)	2023-01-03	一种融合蛋白及其制备司美格鲁肽中间体多肽的方法
WO1988010299A1 (fr)	1988-12-29	Procede de preparation d'une proteine ou d'un polypeptide, sequence d'adn codant pour le polypeptide, microorganisme contenant la sequence d'adn et le polypeptide et utilisation du polypeptide comme preparation pharmaceutique
KR100989413B1 (ko)	2010-10-28	새로운 융합파트너를 이용한 재조합 단백질의 제조방법
KR100368073B1 (ko)	2003-01-24	융합파트너를 이용한 재조합 단백질의 제조방법
CN116478969A (zh)	2023-07-25	胶原酶突变体、促进重组胶原酶分泌表达的方法及其应用
AU4539400A (en)	2000-11-14	Production of pancreatic procarboxy-peptidase b, isoforms and muteins thereof, and their use
JPH0648988B2 (ja)	1994-06-29	トロンビン阻害物質の製造法
CN114805544B (zh)	2022-09-09	一种赖脯胰岛素前体、其重组基因工程菌及其构建方法
KR100407792B1 (ko)	2003-12-01	인간 글루카곤 유사펩타이드를 융합파트너로 이용한재조합 단백질의 제조방법
EP0570244B1 (fr)	1998-02-11	Procédé de préparation de peptides ayant un résidu proline amidé en position C-terminale
CN101157725A (zh)	2008-04-09	人胰岛素类似物的制备方法及用途
JP2650856B2 (ja)	1997-09-10	Ｃ−末端アミド化酵素の製造方法
KR970009082B1 (ko)	1997-06-05	인간 알파 아트리알 나트리 우레틱 인자(human α-arterial natriuretic factor; α-hANF)의 미생물학적 제조방법
CN114075295A (zh)	2022-02-22	一种Boc-人胰岛素融合蛋白包涵体的高效复性液及其复性方法
HK1003839B (en)	1998-11-06	Process for preparing peptides having a c-terminal proline amide
JPH07165792A (ja)	1995-06-27	精製された蛋白質

Legal Events

Date	Code	Title	Description
2007-02-27	MM4A	Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)	Designated state(s): AM AZ BY KZ KG MD TJ TM RU